Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 4/20 | 0.44 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | CFB | P00751 | 7/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21822330 | 0.87 | PIN1 (0.54) | PIN1CFBPKN1PKN2CSNK1A1 | |
| SCHEMBL20495149 | 0.86 | ABL1 (0.42) | RHEBCYP19A1CSNK1A1CSNK1DGSK3B | |
| SCHEMBL13677328 | 0.84 | CSNK1D (0.46) | MAPK10IMPDH2IMPDH1PIN1CFB | |
| SCHEMBL7655142 | 0.84 | NPSR1 (0.53) | IMPDH2IMPDH1PIN1CFB | |
| SCHEMBL1245512 | 0.78 | RHEB (0.49) | MAPK10RHEBIMPDH2IMPDH1PIN1 | |
| SCHEMBL4387879 | 0.76 | IMPDH2 (0.46) | MAPK10RHEBIMPDH2IMPDH1PIN1 | |
| SCHEMBL1358509 | 0.76 | HRH4 (0.41) | — | |
| SCHEMBL14669397 | 0.75 | DGAT1 (0.54) | RHEBCFBPKN1PKN2 | |
| SCHEMBL1509452 | 0.75 | NOS1 (0.38) | CYP19A1 | |
| SCHEMBL5773139 | 0.75 | NOS1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3557998-A1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119395-A1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119395-A1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9107411-B2 | Indolecarboxamides and benzimidazolecarboxamides as insecticides and acaricides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-20140088167-A1 | INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542233-B2 | Compounds, compositions and methods of use | FUS, TFEB, CLN6 | MAPK10 2459/4885RHEB 72/4885IMPDH2 4043/4885 |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | MAPK10 2459/4885RHEB 72/4885IMPDH2 4043/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | MAPK10 2459/4885RHEB 72/4885IMPDH2 4043/4885 |
| US-20140088167-A1 | INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES | AADAC, DDT, AANAT | MAPK10 4850/4885RHEB 4115/4885IMPDH2 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.